retatrutide kidney Extreme Side Effects Followed Overdose of Unapproved Weight-Loss Drug Retatrutide—A Game Changer in Obesity

2-8C after reconstitution, protected from light Use: Laboratory research only not for human or animal consumption This is a patented investigational compound sold for laboratory research only

Weeks 13 to 16: 7.5 mg to 5 mg

State Legislative Landscape in 2025 Despite a significant number of bills in 2023 and 2024 that would have required mandated coverage of GLP-1s in Medicaid, state employee health plans, or for health insurers regulated by the state, only Arkansas, California, Maryland, New Mexico, Pennsylvania, and Texas have introduced legislation mandating coverage in 2025 to date

Department of Health and Human Services Obesity: Health Consequences of Being Overweight. World Health Organization Obesity and Cancer Fact Sheet. National Cancer Institute, U.S

Alcohol use A patient with a history of excess alcohol use must be advised to stop consuming alcohol before starting GLP-1 receptor agonist therapy

Marisa heads up the wellness practice at Radiance